DEBIRI plus capecitabine: a treatment option for refractory liver-dominant metastases from colorectal cancer.
Sign Up to like & getrecommendations! Published in 2017 at "Future oncology"
DOI: 10.2217/fon-2017-0025
Abstract: AIM This single institution Phase II study evaluated drug-eluting beads loaded with irinotecan (DEBIRI) plus capecitabine in pretreated patients with colorectal cancer liver metastases. PATIENTS & METHODS Forty patients with liver-limited or liver-dominant disease, who… read more here.
Keywords: plus capecitabine; colorectal cancer; liver; debiri ... See more keywords